Cabotegravir - Injectable Suspension (CAB LA) ( DrugBank: Cabotegravir )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 256 | Muscle glycogenosis | 1 |
256. Muscle glycogenosis
Clinical trials : 180 / Drugs : 133 - (DrugBank : 29) / Drug target genes : 25 - Drug target pathways : 105
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02938520 (ClinicalTrials.gov) | October 27, 2016 | 15/9/2016 | Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants | A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants | HIV Infections;Glycogen Storage Disease Type II | Drug: Cabotegravir (CAB) tablet;Drug: Rilpivirine (RPV) tablet;Drug: Cabotegravir - Injectable Suspension (CAB LA);Drug: Rilpivirine - Injectable Suspension (RPV LA);Drug: ABC/DTG/3TC STR - Tablet;Drug: DTG Tablet | ViiV Healthcare | Janssen Pharmaceuticals;GlaxoSmithKline | Active, not recruiting | 18 Years | N/A | All | 631 | Phase 3 | United States;Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;South Africa;Spain;United Kingdom |